Drug details:
Molecular formula: C₁₉H₁₈FN₃O₄S

Standard name: 4-[(3-ethoxy-2-hydroxyphenyl)methyl]-N-(4-fluorophenyl)-5-oxo-1,3,4-thiadiazine-2-carboxamide

Curated SMILES: CCOC1=C(O)C(CN2N=C(C(=O)NC3=CC=C(F)C=C3)SCC2=O)=CC=C1

Evidence for compound's anti-virulence activity:

Chlamydia
Related VF: TTSS (Type III secretion system)
Target: Not determined
Drug effect: Inhibits T3SS activity and disrupts progression of the chlaymdial development cycle.
Max phase: Preclinical (in vitro)
Publication:
Zigangirova NA, et al., 2012. Development of Chlamydial Type III Secretion System Inhibitors for Suppression of Acute and Chronic Forms of Chlamydial Infection. Acta Naturae 4(2):87-97.